Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 31, 2018
Event: Entry into a Material Definitive Agreement and Completion of Acquisition of Assets.
Key Financial Metrics and Transaction Details
This filing details an acquisition rather than standard periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Upfront Cash Payment: $750,000 paid to the seller (Gregory Lucas), inclusive of transaction expenses.
- Debt Repayment: Approximately $8,000 of Biocon debt repaid at closing.
- Contingent Consideration: Potential future payments based on net revenue of acquired entities for fiscal years 2019 and 2020, capped at $2,625,000.
- Acquired Entities: 100% of membership interests in Biocon 1, LLC and Aether Water Systems, LLC.
Material Changes and Background
The Company acquired two entities with which it previously held a strategic partnership announced in November 2015. Under the prior arrangement:
- Biocon held exclusive distribution rights for Nephros' custom filter cartridges in the food service market.
- An equipment lease existed between the parties, commencing January 1, 2016, with a 60-month term and monthly rental payments of approximately $1,800 to Nephros.
The acquisition converts this partnership into full ownership of the entities.
Outlook, Risks, and Contingencies
- Future Obligations: The Company is obligated to pay contingent consideration up to $2,625,000 based on the net revenue performance of the acquired entities over the 2019 and 2020 fiscal years.
- Indemnification: The seller (Lucas) has agreed to customary indemnification obligations for a two-year period ending December 31, 2020.
- Financial Statements: Specific financial statements for the acquired business and pro forma financial information are not included in this filing; they will be filed by amendment within the required time period.
Investor Verification Checklist
- Verify the pro forma financial impact of the acquisition once filed by amendment.
- Monitor the net revenue of Biocon and Aether in 2019 and 2020 to assess the likelihood of the $2,625,000 contingent payment cap being reached.
- Review the full Membership Interest Purchase Agreement (to be filed in the Form 10-K) for specific representations, warranties, and limitations on indemnification.
- Confirm the integration status of the acquired entities into Nephros' existing operations.